TCR-Engineered T Cells for Antigen-Specific Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies, particularly immune checkpoint inhibitors, show limited efficacy in 70-80% of cancer patients, highlighting the need for improved methods to enhance and identify mechanisms of immune response, specifically in identifying and utilizing T-cell receptor (TCR) recognizing cancer-specific antigens.
Innovation Solution
Methods involving stimulation of CD8+ cytotoxic T lymphocytes with candidate antigen sequences, capturing immune-active T cells using MHC multimers, and sequencing their TCRs to identify cancer-specific antigens, followed by generating TCR-engineered T cells with antigen-specific cytotoxic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitors are used to treat cancer, then anti-cancer immune activity is boosted, but 70-80% of patients show no or minimum benefit
Solution Approach 1:
The patent segments the immune response by identifying and isolating specific TCRs that recognize cancer-specific antigens. By dividing the complex immune system into identifiable TCR components and their corresponding antigen targets, the invention enables personalized therapy approaches that can be tailored to individual patients' tumor-specific antigens, thereby improving overall treatment efficacy across the patient population.
Solution Approach 2:
The patent changes the parameter of T cell recognition by engineering TCRs with modified specificity and affinity characteristics. By altering the TCR's antigen-binding properties through identification and engineering of specific TCR variants, the therapy can be optimized for different cancer types and patient populations, expanding adaptability while maintaining reliability.
2Reliability
If TCR identification methods are improved to identify cancer-specific antigens, then personalized immunotherapy can be developed, but the process remains difficult and time-consuming
Solution Approach 1:
The patent performs preliminary action by pre-identifying and characterizing TCRs that recognize cancer-specific antigens before patient treatment. The method involves isolating T cells that naturally recognize tumor antigens, sequencing their TCRs, and creating a library of validated TCR-antigen pairs that can be rapidly deployed for personalized therapy, significantly reducing the time required for clinical implementation.
Solution Approach 2:
The patent uses copying by creating recombinant TCR constructs based on naturally occurring TCR sequences identified from patients or donors. These copied TCR genes are then introduced into patient T cells to generate personalized therapies, replicating the successful antigen-recognition capability without requiring de novo identification for each patient.
3Reliability
If TCR-engineered T cells are generated with high antigen-specific cytotoxic activity, then cancer treatment outcomes are enhanced, but the complexity of T cell engineering increases
Solution Approach 1:
The patent extracts only the essential TCR alpha and beta chain genes required for antigen recognition, separating them from the complex whole T cell system. By isolating and engineering only these critical components while retaining the patient's own T cell framework, the method achieves high cytotoxic activity without the need for comprehensive T cell reengineering, thereby reducing overall process complexity.
Solution Approach 2:
The patent creates universal TCR engineering platforms that can be applied across different cancer types and patients. By developing standardized protocols for TCR identification, cloning, and T cell transduction that work across multiple applications, the method reduces the apparent complexity while maintaining high cytotoxic activity through reusable engineering approaches.
Data Source
AI summary
Provided herein are methods to identify TCR-recognizing cancer-specific antigens, and TCR-engineered T cells having antigen-specific cytotoxic activity. Provided herein are engineered T lymphocytes produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the engineered T lymphocytes described herein. Provided herein are antibodies, or fragments thereof, produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the antibodies described herein to a subject. In some embodiments, the therapeutic compositions (e.g., engineered lymphocytes, antibodies, etc.) and methods herein are provided as part of a kit or system.